Total Payments
$151,998
2024 Payments
$9,879
Companies
31
Transactions
443
Medicare Patients
6,739
Medicare Billing
$480,938
Payment Breakdown by Category
Other$141,118 (92.8%)
Food & Beverage$9,870 (6.5%)
Travel$743.67 (0.5%)
Education$266.19 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $141,118 | 64 | 92.8% |
| Food and Beverage | $9,870 | 364 | 6.5% |
| Travel and Lodging | $743.67 | 3 | 0.5% |
| Education | $266.19 | 12 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73,500 | 138 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35,475 | 43 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $12,911 | 27 | $0 (2021) |
| PFIZER INC. | $11,592 | 19 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $6,304 | 8 | $0 (2018) |
| Lilly USA, LLC | $4,545 | 6 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $4,106 | 9 | $0 (2022) |
| Abbott Laboratories | $900.85 | 22 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $644.58 | 37 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $376.40 | 35 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,879 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,004) |
| 2023 | $15,316 | 19 | PFIZER INC. ($7,948) |
| 2022 | $14,507 | 45 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,006) |
| 2021 | $14,472 | 52 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,231) |
| 2020 | $18,195 | 48 | AstraZeneca Pharmaceuticals LP ($7,801) |
| 2019 | $15,437 | 77 | Novartis Pharmaceuticals Corporation ($14,503) |
| 2018 | $26,854 | 71 | Novartis Pharmaceuticals Corporation ($26,103) |
| 2017 | $37,339 | 118 | Novartis Pharmaceuticals Corporation ($25,738) |
All Payment Transactions
443 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $15.66 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 11/12/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $17.13 | General |
| Category: Cardiovascular Device | ||||||
| 10/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $87.22 | General |
| Category: DIABETES | ||||||
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $121.04 | General |
| Category: DIABETES | ||||||
| 09/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 08/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $121.69 | General |
| Category: DIABETES | ||||||
| 08/01/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $26.07 | General |
| Category: Heart Failure | ||||||
| 07/18/2024 | Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 05/21/2024 | Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 02/20/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $780.00 | General |
| Category: Diabetes | ||||||
| 02/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $123.97 | General |
| 11/23/2023 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,525.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 11/15/2023 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/09/2023 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $79.88 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/27/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $260.00 | General |
| Category: Diabetes | ||||||
| 09/11/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $118.90 | General |
| Category: DIABETES | ||||||
| 08/16/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: DIABETES | ||||||
| 08/15/2023 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $16.45 | General |
| Category: Heart Failure and Hypertension | ||||||
| 07/19/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,040.00 | General |
| Category: DIABETES | ||||||
| 07/06/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 06/07/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $110.70 | General |
| Category: DIABETES | ||||||
| 06/06/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $9.64 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,655 | 2,684 | $273,754 | $130,025 |
| 2022 | 12 | 1,510 | 2,075 | $229,009 | $109,383 |
| 2021 | 10 | 1,487 | 1,996 | $237,644 | $116,117 |
| 2020 | 10 | 2,087 | 2,943 | $261,923 | $125,413 |
Total Patients
6,739
Total Services
9,698
Medicare Billing
$480,938
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 275 | 491 | $131,097 | $61,794 | 47.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 113 | 116 | $33,756 | $15,182 | 45.0% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 114 | 351 | $18,252 | $13,051 | 71.5% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 119 | 447 | $18,774 | $8,275 | 44.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 28 | 48 | $15,360 | $7,829 | 51.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $13,692 | $6,714 | 49.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 69 | 75 | $14,325 | $6,416 | 44.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 770 | 968 | $17,424 | $5,629 | 32.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 42 | $6,258 | $3,733 | 59.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 69 | 81 | $2,835 | $838.14 | 29.6% |
| 93290 | Evaluation of implantable heart and blood vessel monitoring system | Office | 2023 | 23 | 23 | $1,981 | $564.04 | 28.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 222 | 343 | $91,581 | $45,983 | 50.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 181 | 229 | $43,739 | $19,747 | 45.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 95 | 98 | $28,518 | $14,529 | 50.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 26 | 41 | $13,120 | $7,001 | 53.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 708 | 901 | $16,218 | $5,378 | 33.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 33 | 52 | $7,748 | $4,105 | 53.0% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2022 | 78 | 192 | $8,064 | $3,869 | 48.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $5,868 | $2,917 | 49.7% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2022 | 62 | 103 | $5,354 | $2,330 | 43.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $4,446 | $1,916 | 43.1% |
| 93290 | Evaluation of implantable heart and blood vessel monitoring system | Office | 2022 | 21 | 31 | $2,638 | $1,090 | 41.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 48 | 49 | $1,715 | $517.95 | 30.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 286 | 425 | $80,887 | $39,216 | 48.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 150 | 190 | $50,568 | $26,125 | 51.7% |
About Dr. Lynne Wagoner, MD
Dr. Lynne Wagoner, MD is a Cardiovascular Disease healthcare provider based in Fairfield, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831147099.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lynne Wagoner, MD has received a total of $151,998 in payments from pharmaceutical and medical device companies, with $9,879 received in 2024. These payments were reported across 443 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($141,118).
As a Medicare-enrolled provider, Wagoner has provided services to 6,739 Medicare beneficiaries, totaling 9,698 services with total Medicare billing of $480,938. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Advanced Heart Failure and Transplant Cardiology
- Location Fairfield, OH
- Active Since 05/04/2006
- Last Updated 01/25/2017
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1831147099
Products in Payments
- ENTRESTO (Drug) $73,435
- JARDIANCE (Drug) $39,625
- FARXIGA (Drug) $12,713
- VYNDAQEL (Drug) $11,500
- SAMSCA (Drug) $6,304
- Adempas (Drug) $4,106
- XARELTO (Drug) $376.40
- OPSUMIT (Drug) $350.30
- ORENITRAM (Drug) $326.22
- Corlanor (Drug) $325.16
- CardioMEMS HF System (Device) $219.35
- OPSUMIT MACITENTAN (Drug) $211.97
- HeartMate (Device) $172.01
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $154.82
- PRADAXA (Drug) $148.11
- Circulatory Support (Device) $134.70
- PCI Optimization (Device) $115.66
- BRILINTA (Drug) $105.41
- ELIQUIS (Drug) $98.41
- ONPATTRO (Drug) $91.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Fairfield
Robert Winslow, M.d, M.D
Cardiovascular Disease — Payments: $155,333
Cardiovascular Disease $155,333
Adam Schussheim, M.d, M.D
Cardiovascular Disease — Payments: $146,029
Cardiovascular Disease $146,029
Dr. Ho-Hin Choy, M.d, M.D
Cardiovascular Disease — Payments: $66,203
Cardiovascular Disease $66,203
Ram Gordon, Md, MD
Cardiovascular Disease — Payments: $31,625
Cardiovascular Disease $31,625
Dr. Milind Dhond, M. D, M. D
Cardiovascular Disease — Payments: $22,399
Cardiovascular Disease $22,399
Jeffrey Breneisen, Md, MD
Cardiovascular Disease — Payments: $19,530
Cardiovascular Disease $19,530